CVM - CEL-SCI Corp Stock Price, Fair Value and News

1.29USD-0.11 (-7.86%)Delayed

Market Summary

USD1.29-0.11

Delayed

-7.86%

CVM Alerts

3 major insider buys recently.

CVM Stock Price

View Fullscreen

CVM RSI Chart

CVM Valuation

Market Cap

69.9M

Price/Earnings (Trailing)

-2.33

Price/Sales (Trailing)

167.36

EV/EBITDA

-2.41

Price/Free Cashflow

-3.43

CVM Price/Sales (Trailing)

CVM Profitability

EBT Margin

-7536.20%

Return on Equity

-209.39%

Return on Assets

-99.68%

Free Cashflow Yield

-29.16%

CVM Fundamentals

CVM Revenue

Revenue (TTM)

462.8K

CVM Earnings

Earnings (TTM)

-30.0M

Earnings Growth (Yr)

13.16%

Earnings Growth (Qtr)

-7.98%

Breaking Down CVM Revenue

Last 7 days

-9.1%

Last 30 days

-14.0%

Last 90 days

-44.9%

Trailing 12 Months

-49.4%

How does CVM drawdown profile look like?

CVM Financial Health

Current Ratio

1.67

CVM Investor Care

Shares Dilution (1Y)

21.12%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	469.7K	466.2K	462.8K	0
2018	0	0	476.6K	473.1K
2017	207.5K	342.0K	0	0
2016	98.0K	85.5K	73.0K	0
2015	116.9K	112.5K	110.5K	0
2014	120.0K	121.4K	122.9K	120.2K
2013	116.6K	116.8K	117.1K	118.5K
2012	536.1K	326.1K	116.1K	116.3K
2011	554.7K	755.4K	956.2K	746.1K
2010	0	116.7K	153.3K	354.0K
2009	0	0	80.1K	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CEL-SCI Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	prichep patricia b	bought	11,120	1.39	8,000	senior vice president
May 08, 2024	kersten geert r	bought	41,700	1.39	30,000	chief executive officer
May 08, 2024	watson robert eugene	bought	27,800	1.39	20,000	-
Mar 29, 2024	kersten geert r	acquired	5,174	1.91	2,709	chief executive officer
Mar 29, 2024	talor eyal	acquired	2,398	1.91	1,256	chief scientific officer
Mar 29, 2024	prichep patricia b	acquired	4,289	1.91	2,246	senior vice president
Dec 29, 2023	talor eyal	acquired	2,399	2.72	882	chief scientific officer
Dec 29, 2023	kersten geert r	acquired	4,947	2.72	1,819	chief executive officer
Dec 29, 2023	prichep patricia b	acquired	4,289	2.72	1,577	senior vice president
Sep 29, 2023	prichep patricia b	acquired	4,290	1.25	3,432	senior vice president

Which funds bought or sold CVM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-2.24	-51,360	112,458	-%
May 16, 2024	Tidal Investments LLC	new	-	26,532	26,532	-%
May 15, 2024	Squarepoint Ops LLC	new	-	21,612	21,612	-%
May 15, 2024	Man Group plc	reduced	-54.13	-79,135	37,602	-%
May 15, 2024	Community Bank, N.A.	unchanged	-	-410	950	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-66.48	-33,687	10,371	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	22,099	22,099	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	133,085	133,085	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	58.63	31,160	304,645	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	reduced	-0.02	-7,781	18,336	-%

Are Funds Buying or Selling CVM?

Are funds buying CVM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CVM

No. of Funds

CVM Alerts

3 major insider buys recently.

Unveiling CEL-SCI Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 08, 2023	state street corp	0.5%	218,207	SC 13G/A
Jul 08, 2022	blackrock inc.	2.7%	1,153,102	SC 13G
Apr 11, 2022	state street corp	2.27%	980,339	SC 13G/A
Feb 11, 2022	state street corp	7.79%	3,368,998	SC 13G/A
Feb 01, 2022	blackrock inc.	6.8%	2,942,209	SC 13G/A
Oct 12, 2021	state street corp	10.64%	4,576,724	SC 13G/A
Jan 29, 2021	blackrock inc.	6.2%	2,472,437	SC 13G/A
Feb 07, 2020	blackrock inc.	5.6%	1,996,547	SC 13G

Recent SEC filings of CEL-SCI Corp

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 10, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
Apr 23, 2024	8-K	Current Report
Apr 23, 2024	3	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading

Peers (Alternatives to CEL-SCI Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

CEL-SCI Corp News

Latest updates

CEL-SCI Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2017Q2	2017Q1	2016Q3	2016Q2	2016Q1	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1
Revenue	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	7.5%	6.00	5.00	4.00	5.00	4.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-1.0%	2.00	2.00	2.00	2.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	14.3%	3.00	3.00	3.00	3.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-0.7%	-0.45	-0.44	-0.46	-0.45	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-Infinity%	-4.85	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	59.9%	-4.85	-12.08	-6.45	1.00	-14.93	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	4.7%	30.00	29.00	31.00	32.00	38.00	45.00	51.00	57.00	64.00	70.00	76.00	80.00	48.00	50.00	41.00	44.00	37.00	31.00	28.00	28.00	25.00
Current Assets	38.3%	9.00	6.00	7.00	8.00	13.00	20.00	25.00	31.00	37.00	42.00	45.00	50.00	20.00	24.00	18.00	23.00	16.00	11.00	10.00	11.00	7.00
Cash Equivalents	63.8%	5.00	3.00	4.00	5.00	10.00	18.00	23.00	28.00	34.00	37.00	36.00	36.00	6.00	22.00	16.00	20.00	14.00	9.00	8.00	9.00	6.00
Inventory	-100.0%	-	2.00	2.00	-	-	-	2.00	-	-	-	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-5.5%	9.00	10.00	10.00	11.00	11.00	12.00	12.00	12.00	13.00	13.00	14.00	14.00	13.00	9.00	6.00	4.00	3.00	3.00	16.00	16.00	16.00
Liabilities	-2.0%	16.00	16.00	17.00	18.00	18.00	18.00	18.00	18.00	19.00	18.00	19.00	20.00	19.00	21.00	21.00	23.00	23.00	23.00	22.00	27.00	24.00
Current Liabilities	4.5%	5.00	5.00	6.00	5.00	5.00	5.00	5.00	4.00	4.00	3.00	4.00	5.00	6.00	7.00	4.00	5.00	5.00	5.00	3.00	4.00	5.00
Shareholder's Equity	13.1%	14.00	13.00	13.00	15.00	20.00	27.00	32.00	39.00	45.00	51.00	57.00	60.00	29.00	29.00	20.00	21.00	14.00	9.00	5.00	1.00	1.00
Retained Earnings	-1.5%	-501	-493	-487	-479	-471	-462	-454	-446	-436	-426	-418	-409	-401	-389	-381	-376	-366	-357	-353	-348	-336
Additional Paid-In Capital	1.8%	515	506	500	494	491	489	487	485	481	478	474	469	430	418	401	397	380	366	359	350	337
Shares Outstanding	8.1%	54.00	50.00	47.00	45.00	44.00	44.00	43.00	43.00	43.00	43.00	43.00	41.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	-	-	98.00	-	-	-	596	-	-	-	412	-	-	-	100

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	7.4%	-4,527	-4,887	-5,044	-5,665	-7,471	-4,666	-4,913	-5,789	-2,731	-4,805	-4,802	-5,200	-4,956	-3,827	-3,586	-3,699	-3,888	-4,101	-3,887	-4,643	-3,632
Share Based Compensation	3.5%	1,433	1,384	1,310	1,540	1,743	1,693	2,287	2,448	3,393	3,262	3,595	3,511	3,283	3,296	3,423	3,109	1,781	1,800	1,802	1,522	531
Cashflow From Investing	100.0%	-	-64.86	-10.37	-196	-111	-53.58	-16.07	-70.96	-533	6,112	4,590	-1,999	-14,624	-3,149	-1,124	-803	-657	-109	-49.04	-58.22	-156
Cashflow From Financing	62.9%	6,596	4,048	4,066	952	-388	65.00	-471	-348	438	-256	315	36,726	4,152	13,329	83.00	10,310	9,492	5,150	2,895	8,673	2,621

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CVM Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)
Research and development	$ 4,628,535	$ 6,083,488	$ 8,981,044	$ 11,476,034
General and administrative	2,447,413	2,092,758	4,580,791	4,350,761
Total operating expenses	7,075,948	8,176,246	13,561,835	15,826,795
Operating loss	(7,075,948)	(8,176,246)	(13,561,835)	(15,826,795)
Interest expense, net	(182,701)	(159,063)	(380,397)	(311,852)
Other expense	(13,758)	(7,500)	(12,183)	(57,671)
Net loss	(7,244,891)	(8,342,809)	(13,954,415)	(16,196,318)
Modification of warrants			0	(171,552)
Net loss available to common shareholders	$ (7,244,891)	$ (8,342,809)	$ (13,954,415)	$ (16,367,870)
Net loss per common share - basic and diluted	$ (0.14)	$ (0.19)	$ (0.28)	$ (0.38)
Weighted average common shares outstanding - basic and diluted	52,006,442	43,588,381	50,228,860	43,513,571

CVM Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 5,309,321	$ 4,145,735
Prepaid expenses	696,648	520,368
Supplies used for R&D and manufacturing	2,489,284	2,248,072
Deposits	16,129	4,245
Total current assets	8,511,382	6,918,420
Finance lease right of use assets	8,251,453	9,131,987
Operating lease right of use assets	1,598,879	1,698,243
Property and equipment, net	9,113,284	10,188,126
Patent costs, net	180,482	197,704
Deposits	2,319,101	2,319,101
Supplies used for R&D and manufacturing	73,524	74,669
Total assets	30,048,105	30,528,250
Current liabilities:
Accounts payable	1,015,969	2,009,786
Accrued expenses	1,219,399	1,049,581
Due to employees	751,607	557,244
Finance lease obligation, current portion	1,888,767	1,771,804
Operating lease obligation, current portion	211,275	197,431
Total current liabilities	5,087,017	5,585,846
Finance lease obligations, net of current portion	8,987,319	9,949,565
Operating lease obligations, net of current portion	1,544,126	1,652,949
Other liabilities	125,000	125,000
Total liabilities	15,743,462	17,313,360
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding	0	0
Common stock, $.01 par value; 600,000,000 shares authorized; 54,083,718 and 47,422,304 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively	540,837	474,223
Additional paid-in capital	514,809,617	499,832,063
Accumulated deficit	(501,045,811)	(487,091,396)
Total stockholders' equity	14,304,643	13,214,890
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 30,048,105	$ 30,528,250

About CEL-SCI Corp

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

WEBSITE	https://cel-sci.com
INDUSTRY	Biotechnology

CEL-SCI Corp Frequently Asked Questions

What is the ticker symbol for CEL-SCI Corp? What does CVM stand for in stocks?

CVM is the stock ticker symbol of CEL-SCI Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CEL-SCI Corp (CVM)?

As of Fri May 17 2024, market cap of CEL-SCI Corp is 69.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CVM stock?

You can check CVM's fair value in chart for subscribers.

What is the fair value of CVM stock?

You can check CVM's fair value in chart for subscribers. The fair value of CEL-SCI Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CEL-SCI Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CVM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CEL-SCI Corp a good stock to buy?

The fair value guage provides a quick view whether CVM is over valued or under valued. Whether CEL-SCI Corp is cheap or expensive depends on the assumptions which impact CEL-SCI Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CVM.

What is CEL-SCI Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CVM's PE ratio (Price to Earnings) is -2.33 and Price to Sales (PS) ratio is 167.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CVM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CEL-SCI Corp's stock?

In the past 10 years, CEL-SCI Corp has provided -0.265 (multiply by 100 for percentage) rate of return.